Novartis plans to invest USD 23 billion over next 5 years in US based infrastructure
Advertisement
East Hanover: Novartis, a global medicines company, has announced a planned USD 23 billion investment over 5 years in US-based infrastructure, ensuring all key Novartis medicines for US patients will be made in the United States.
This commitment enables Novartis to expand on its current manufacturing, research and technology presence across the country with 10 facilities, including 7 brand new facilities, creating nearly 1,000 new jobs at Novartis and approximately 4,000 additional US jobs.
The production capacity will cover both active pharmaceutical ingredients (API) and biologics drug substance, as well as secondary production and packaging.
Over the next 5 years, Novartis will:
- Establish 1 biomedical research innovation hub in San Diego, CA, its second global R&D hub in the US
- Build 4 new manufacturing facilities in soon-to-be-determined states, including 3 that will make biologics drug substances, drug products, device assembly and packaging, and 1 facility that will make chemical drug substances, oral solids dosage forms and packaging
- Build 2 new radioligand therapy (RLT) manufacturing facilities in Florida and Texas
- Expand 3 RLT manufacturing facilities in Indianapolis, IN, Millburn, NJ, and Carlsbad, CA
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.